Management of Left Main Coronary Artery Disease

Clinical Scenarios Favoring Stenting Over CABG

The European Society of Cardiology recommends percutaneous coronary intervention with stenting for left main coronary artery disease in patients at prohibitively high surgical risk (EuroSCORE >10%), those with ostial or midshaft LMCA lesions, or as bailout therapy in acute presentations with hemodynamic instability 1, 2
Patients with serious comorbidities, including chronic lung disease, poor performance status, advanced age intolerant of major surgery, or limited life expectancy, should undergo PCI rather than CABG, as recommended by the American Heart Association 2

The American College of Cardiology states that CABG remains the gold standard for complex LMCA disease with distal LMCA bifurcation lesions requiring two-stent techniques, severe calcification or tortuosity unsuitable for stenting, concomitant diffuse multivessel disease, severely compromised left ventricular function, or complex in-stent restenosis unsuitable for repeat stenting 2
Distal LMCA bifurcation lesions have significantly higher restenosis rates (up to 42%) and target lesion revascularization rates (up to 38%) compared to ostial or midshaft LMCA lesions, according to the European Heart Journal 5, 6

The provisional side-branch stenting approach is recommended as the initial strategy for bifurcation lesions when the side branch has only mild-to-moderate focal ostial disease, with a target lesion revascularization rate of less than 5% for distal LMCA lesions, as stated by the American Heart Association 7, 8
Elective double stenting is reasonable when bifurcation involves a large side branch with high occlusion risk and low likelihood of successful reaccess, with available techniques including T-stenting, crush stenting, culotte stenting, and simultaneous kissing stenting (Y-stenting), according to the European Society of Cardiology 5, 6

IVUS assessment is advocated in most LMCA stenting cases for optimal stent deployment, and is reasonable for assessment of angiographically indeterminate LMCA disease, as recommended by the American College of Cardiology 5, 6, 8
Drug-eluting stents demonstrate significantly lower restenosis (6% vs 22%) and target lesion revascularization (2% vs 16%) compared to bare-metal stents, according to the European Heart Journal 3

Dual antiplatelet therapy with aspirin plus clopidogrel should be continued for at least 12 months after DES placement, and aspirin 81 mg daily is reasonable in preference to higher maintenance doses, as stated by the American Heart Association 8
Premature discontinuation of antiplatelet therapy dramatically increases stent thrombosis risk, which is catastrophic in LMCA locations, according to the European Society of Cardiology 5, 6

Patient selection is crucial and depends on LMCA lesion location, extent of concomitant multivessel disease, left ventricular ejection fraction, presence of diabetes mellitus, surgical risk assessment (EuroSCORE), and patient/physician preference after thorough discussion of risks and benefits, as recommended by the American College of Cardiology 1, 2, 3